Institution
Saint Louis University
Education•St Louis, Missouri, United States•
About: Saint Louis University is a education organization based out in St Louis, Missouri, United States. It is known for research contribution in the topics: Population & Health care. The organization has 18927 authors who have published 34895 publications receiving 1267475 citations. The organization is also known as: SLU & St. Louis University.
Topics: Population, Health care, Poison control, Transplantation, Medicine
Papers published on a yearly basis
Papers
More filters
Saint Louis University1, University of California, San Diego2, Virginia Commonwealth University3, Columbia University4, Johns Hopkins University5, Duke University6, Indiana University – Purdue University Indianapolis7, Case Western Reserve University8, University of California, San Francisco9, Virginia Mason Medical Center10, Cleveland Clinic11, Washington University in St. Louis12, National Institutes of Health13
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.
1,798 citations
University of Colorado Denver1, Linköping University2, Hoffmann-La Roche3, Houston Methodist Hospital4, The Heart Research Institute5, Saint Louis University6, University of Oslo7, University of Glasgow8, University of Adelaide9, Cedars-Sinai Medical Center10, Montreal Heart Institute11, Mayo Clinic12
TL;DR: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
Abstract: Background In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. Methods We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation. Results At the time of randomization, the mean HDL cholesterol level was 42 mg per deciliter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol level was 76 ...
1,773 citations
National Institutes of Health1, Saint Louis University2, University of California, Berkeley3, United States Environmental Protection Agency4, University of Oxford5, Louisiana State University6, Fudan University7, Tata Institute of Fundamental Research8, Queen Mary University of London9, University of Minnesota10, Finnish Institute of Occupational Health11, University of Buenos Aires12, Johns Hopkins University13, Ohio State University14, American Cancer Society15, University of Paris16, University of Turin17, University of Southern California18, Russian Academy19
1,761 citations
TL;DR: Overall, there was no significant difference in the rates of death and major cardiovascular events between patients undergoing prompt revascularization and those undergoing medical therapy or between strategies of insulin sensitization and insulin provision.
Abstract: At 5 years, rates of survival did not differ significantly between the revascularization group (88.3%) and the medical therapy group (87.8%, P = 0.97) or between the in sulin sensitization group (88.2%) and the insulin provision group (87.9%, P = 0.89). The rates of freedom from major cardiovascular events also did not differ signifi cantly among the groups: 77.2% in the revascularization group and 75.9% in the medical treatment group (P = 0.70) and 77.7% in the insulin sensitization group and 75.4% in the insulin provision group (P = 0.13). In the PCI stratum, there was no sig nificant difference in primary end points between the revascularization group and the medical therapy group. In the CABG stratum, the rate of major cardiovascular events was significantly lower in the revascularization group (22.4%) than in the medical therapy group (30.5%, P = 0.01; P = 0.002 for interaction between stratum and study group). Adverse events and serious adverse events were generally similar among the groups, although severe hypoglycemia was more frequent in the insulin provision group (9.2%) than in the insulin sensitization group (5.9%, P = 0.003). Conclusions Overall, there was no significant difference in the rates of death and major cardio vascular events between patients undergoing prompt revascularization and those undergoing medical therapy or between strategies of insulin sensitization and in sulin provision. (ClinicalTrials.gov number, NCT00006305.)
1,743 citations
TL;DR: Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients.
1,715 citations
Authors
Showing all 19076 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Douglas G. Altman | 253 | 1001 | 680344 |
| John E. Morley | 154 | 1377 | 97021 |
| Roberto Romero | 151 | 1516 | 108321 |
| Daniel S. Berman | 141 | 1363 | 86136 |
| Gregory J. Gores | 141 | 686 | 66269 |
| Thomas J. Smith | 140 | 1775 | 113919 |
| Richard T. Lee | 131 | 810 | 62164 |
| George K. Aghajanian | 121 | 277 | 48203 |
| Reza Malekzadeh | 118 | 900 | 139272 |
| Robert N. Weinreb | 117 | 1124 | 59101 |
| Leslee J. Shaw | 116 | 808 | 61598 |
| Thomas J. Ryan | 116 | 675 | 67462 |
| Josep M. Llovet | 116 | 399 | 83871 |
| Robert V. Farese | 115 | 473 | 48754 |
| Michael Horowitz | 112 | 982 | 46952 |